Source

Commission Implementing Regulation (EU) 2023/918 of 4 May 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances aclonifen, ametoctradin, beflubutamid, benthiavalicarb, boscalid, captan, clethodim, cycloxydim, cyflumetofen, dazomet, diclofop, dimethomorph, ethephon, fenazaquin, fluopicolide, fluoxastrobin, flurochloridone, folpet, formetanate, Helicoverpa armigera nucleopolyhedrovirus, hymexazol, indolylbutyric acid, mandipropamid, metalaxyl, metaldehyde, metam, metazachlor, metribuzin, milbemectin, paclobutrazol, penoxsulam, phenmedipham, pirimiphos-methyl, propamocarb, proquinazid, prothioconazole, S-metolachlor, Spodoptera littoralis nucleopolyhedrovirus, Trichoderma asperellum strain T34 and Trichoderma atroviride strain I-1237 (Text with EEA relevance)

Implementing Regulation (EU) 2023/918 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

Open ↗

This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union .

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows: 1. Part A is amended as follows: (1) in the sixth column, expiration of approval, of row 88, Phenmedipham, the date is replaced by ‘15 February 2025’; (2) in the sixth column, expiration of approval, of row 97, S-metolachlor, the date is replaced by ‘15 November 2024’; (3) in the sixth column, expiration of approval, of row 110, Milbemectin, the date is replaced by ‘15 February 2025’; (4) in the sixth column, expiration of approval, of row 142, Ethephon, the date is replaced by ‘15 November 2024’; (5) in the sixth column, expiration of approval, of row 145, Captan, the date is replaced by ‘15 November 2024’; (6) in the sixth column, expiration of approval, of row 146, Folpet, the date is replaced by ‘15 February 2025’; (7) in the sixth column, expiration of approval, of row 147, Formetanate, the date is replaced by ‘15 February 2025’; (8) in the sixth column, expiration of approval, of row 150, Dimethomorph, the date is replaced by ‘15 February 2025’; (9) in the sixth column, expiration of approval, of row 152, Metribuzin, the date is replaced by ‘15 February 2025’; (10) in the sixth column, expiration of approval, of row 154, Propamocarb, the date is replaced by ‘15 June 2025’; (11) in the sixth column, expiration of approval, of row 156, Pirimiphos-methyl, the date is replaced by ‘15 June 2025’; (12) in the sixth column, expiration of approval, of row 158, Beflubutamid, the date is replaced by ‘31 October 2026’; (13) in the sixth column, expiration of approval, of row 163, Benthiavalicarb, the date is replaced by ‘15 November 2024’; (14) in the sixth column, expiration of approval, of row 164, Boscalid, the date is replaced by ‘15 April 2026’; (15) in the sixth column, expiration of approval, of row 166, Fluoxastrobin, the date is replaced by ‘15 June 2025’; (16) in the sixth column, expiration of approval, of row 168, Prothioconazole, the date is replaced by ‘15 August 2025’; (17) in the sixth column, expiration of approval, of row 215, Aclonifen, the date is replaced by ‘31 October 2026’; (18) in the sixth column, expiration of approval, of row 217, Metazachlor, the date is replaced by ‘31 October 2026’; (19) in the sixth column, expiration of approval, of row 297, Fluopicolide, the date is replaced by ‘31 August 2026’; (20) in the sixth column, expiration of approval, of row 301, Penoxsulam, the date is replaced by ‘15 May 2026’; (21) in the sixth column, expiration of approval, of row 302, Proquinazid, the date is replaced by ‘15 May 2026’; (22) in the sixth column, expiration of approval, of row 304, Metalaxyl, the date is replaced by ‘30 September 2026’; (23) in the sixth column, expiration of approval, of row 316, Cycloxydim, the date is replaced by ‘31 August 2026’; (24) in the sixth column, expiration of approval, of row 322, Hymexazol, the date is replaced by ‘31 August 2026’; (25) in the sixth column, expiration of approval, of row 326, Indolylbutyric acid, the date is replaced by ‘15 March 2026’; (26) in the sixth column, expiration of approval, of row 329, Clethodim, the date is replaced by ‘31 August 2026’; (27) in the sixth column, expiration of approval, of row 339, Dazomet, the date is replaced by ‘31 August 2026’; (28) in the sixth column, expiration of approval, of row 340, Metaldehyde, the date is replaced by ‘31 August 2026’; (29) in the sixth column, expiration of approval, of row 342, Fenazaquin, the date is replaced by ‘31 August 2026’; (30) in the sixth column, expiration of approval, of row 344, Diclofop, the date is replaced by ‘31 August 2026’; (31) in the sixth column, expiration of approval, of row 348, Paclobutrazol, the date is replaced by ‘31 August 2026’; (32) in the sixth column, expiration of approval, of row 354, Flurochloridone, the date is replaced by ‘15 March 2026’. 2. Part B is amended as follows: (1) in the sixth column, expiration of approval, of row 22, Metam, the date is replaced by ‘30 November 2025’; (2) in the sixth column, expiration of approval, of row 29, Trichoderma asperellum strain T34, the date is replaced by ‘31 October 2025’; (3) in the sixth column, expiration of approval, of row 31, Cyflumetofen, the date is replaced by ‘31 October 2025’; (4) in the sixth column, expiration of approval, of row 32, Trichoderma atroviride strain I-1237, the date is replaced by ‘31 October 2025’; (5) in the sixth column, expiration of approval, of row 33, Ametoctradin, the date is replaced by ‘31 December 2025’; (6) in the sixth column, expiration of approval, of row 34, Mandipropamid, the date is replaced by ‘31 December 2025’; (7) in the sixth column, expiration of approval, of row 38, Helicoverpa armigera nucleopolyhedrovirus , the date is replaced by ‘31 October 2025’; (8) in the sixth column, expiration of approval, of row 42, Spodoptera littoralis nucleopolyhedrovirus , the date is replaced by ‘31 October 2025’.

Other acts of the same type

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview